News

Investor's Business Daily on MSN4d

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
PharmExec5d

Recapping the Sarepta Saga—And Implications for Industry

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...
Fierce Biotech12d

Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...
MedCity News11mon

Sarepta Gene Therapy Misses in Phase 3; Prospects Now Rely on FDA ...

Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy fell short of its main Phase 3 goal, but the firm contends the full body of evidence supports expanding the therapy’s label to ...

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
FierceBiotech2y

FDA questions benefits, risks of Sarepta DMD gene therapy - Fierce Biotech

Sarepta says that the risk of patients dropping out once SRP-9001 reaches the market is “extremely low” because there are 45 patients in the trial outside the U.S., which will be the only ...